ATOS - Atossa Therapeutics backing Endoxifen in the fight against breast cancer

(NewsDirect)

Atossa Therapeutics (NASDAQ:ATOS)President & CEO Dr. Steven Quay joins Thomas Warner from Proactiveto speak about the latest developments in his and the clinical-stagebiopharma company's fight against breast cancer.

Dr. Quay gives an overview of ongoingclinical trials centered around their innovative drug, oral Endoxifen.The drug combines oestrogen receptor degradation, suppression, and PKCbeta inhibition to combat breast cancer. The trials are conducted atdifferent stages of breast cancer management. One focus is on breastcancer prevention, specifically targeting high mammographic breastdensity, a significant risk factor.

Dr. Quay emphasises the link between density and cancer risk,noting the potential for changing mammograms' readability andreducing future risk. He goes on to talk about a trial of Endoxifenduring what is known as the neoadjuvant window, the period betweendiagnosis and initial treatment, which is aimed at rapidly reducingtumour activity after diagnosis. These trials, held at Mayo Clinic andUCSF, test the drug's impact on oestrogen-driven cancers, wherecurrent treatments often fall short.

Additionally, the CEO discussed Atossa's broadermotivations, underscoring breast cancer's prevalence and theimmense impact it has on individuals and society. He goes on todiscuss the company's financial position. with approximately $99.4million on the balance sheet as of Q2, enabling continued research anddevelopment. Dr. Quay also reveals research collaborations at WeillCornell Medical Centre targeting triple-negative breast cancer, aparticularly aggressive form. These efforts seek to transform it intoa more treatable type, potentially revolutionising treatment options.

Contact Details

Proactive Investors

+1604-688-8158

na-editorial@proactiveinvestors.com

Copyright (c) 2023 TheNewswire - All rights reserved.